Back to the Top
The following message was posted to: PharmPK
Dear Group,
Warm Greetings on New Year.
I would highly appreciate if anyone can update the recent
trends on
"Non-invasive
pre-clinical pharmacokinetics using various imaging Techniques viz.,
PET,
Fluorescent
scan etc.," on regulatory standpoint .
I believe this real time imaging pharmacokinetics would help us to
understand the PK/
PD effectively than any other conventional approaches.
Thanks in advance.
Regds,
Syed Mustafa,
Drug Metabolism & Pharmacokinetics,
Orchid Research & Development Centre,
Plot No: 476/14, Old Mahabalipuram Road,
Sholinganallur,
Chennai: 600 119
INDIA
Back to the Top
The following message was posted to: PharmPK
Syed:
Is the wording you put between quotes ("Non-invasive pre-clinical
pharmacokinetics using various imaging Techniques viz., PET,
Fluorescent scan etc.,") your own wording or something from another
document?
I could not agree more with your statement:
"this real time [noninvasive] imaging pharmacokinetics would help us
to understand the PK/ PD effectively [better] than any other
conventional approaches"
--
Professor Walter Wolf, Ph.D. Distinguished Professor of
Pharmaceutical Sciences
Director, Pharmacokinetic Imaging Program
Department of Pharmaceutical Sciences, School of Pharmacy
Chair, Biomedical Imaging Science Initiative
University of Southern California 1985 Zonal Ave., Los Angeles, CA
90089-9121
E-Mail: wwolfw.-at-.usc.edu
Telephone: 323-442-1405
Fax: 323-442-9804
http://www.usc.edu/research/initiatives/biomedical_imaging/index.html
Back to the Top
The following message was posted to: PharmPK
Syed:
Is the wording you put between quotes ("Non-invasive pre-clinical
pharmacokinetics using various imaging Techniques viz., PET,
Fluorescent scan etc.,") your own wording or something from another
document?
I could not agree more with your statement:
"this real time [noninvasive] imaging pharmacokinetics would help us
to understand the PK/ PD effectively [better] than any other
conventional approaches"
--
Professor Walter Wolf, Ph.D. Distinguished Professor of
Pharmaceutical Sciences
Director, Pharmacokinetic Imaging Program
Department of Pharmaceutical Sciences, School of Pharmacy
Chair, Biomedical Imaging Science Initiative
University of Southern California 1985 Zonal Ave., Los Angeles, CA
90089-9121
E-Mail: wwolfw.-a-.usc.edu
Telephone: 323-442-1405
Fax: 323-442-9804
http://www.usc.edu/research/initiatives/biomedical_imaging/index.html
Back to the Top
Here is some of my recent reading on this "non-invasive PK" bit:
1, Nicolas R Bolo Ph.D, Yann Hode MD, Jean-Francois Nedelec Ph.D,
Eric Laine MD, Gabrielle Wagner Ph.D and Jean-Paul Macher MD. Brain
Pharmacokinetics and Tissue Distribution In Vivo of Fluvoxamine and
Fluoxetine by Fluorine Magnetic Resonance Spectroscopy.
Neuropsychopharmacology (2000) 23 428-438.10.1038/sj.npp.1395524
2, Maartje M L de Win, Jan B A Habraken, Liesbeth Reneman1, Wim van
den Brink, Gerard J den Heeten1 and Jan Booij. Validation of [123I]-
CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a
Double-Blind, Placebo-Controlled, Crossover Study with the Selective
Serotonin Reuptake Inhibitor Citalopram. Neuropsychopharmacology
(2005) 30, 996-1005, advance online publication, 16 March 2005;
3, Johannes Tauscher, Bernd Kuefferle, Susanne Asenbaum, Sitra
Tauscher-Wisniewski
Siegfried Kasper. Striatal dopamine-2 receptor occupancy as measured
with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in
patients treated with atypical antipsychotics and haloperidol.
Psychopharmacology (2002) 162:42-49, DOI 10.1007/s00213-002-1082-6
4, Kjel Erlandsson, Tharani Sivananthan, Dominic Lui, Andrea Spezzi,
Caroline E. Townsend, Song Mu,Richard Lucas, Steven Warrington, Peter
J. Ell. Measuring SSRI occupancy of SERT using the novel tracer [123I]
ADAM: a SPECT validation study. European Journal of Nuclear Medicine
and Molecular Imaging Vol. 32, No. 11, November 2005
btw, SPECT is more available and less expensive than PET in medical
centers.
Best regards,
Zhang Hao M.D.
Clinical Pharmacology and Experimental Medicine
UCB Pharma R&D
Chemin du Foriest
Braine-l'Alleud
B-1420 Belgium
Tel: +32-2-386 6035
Fax: +32-2-386 3537
Back to the Top
The following message was posted to: PharmPK
Hao Zhang:
You have listed some interesting recent references to non-invasive
PK. However, you have keft out some very critical ones which I am
listing below:
1. The first (to my knowledge) analysis of a complex model (7
compartments, 8 rate constants) was published in 1980:
Radiopharmacokinetics of Pt-195m-Cisplatin. R.C. Manaka and W. Wolf,
In "Cisplatin - Current Status and New Developments", S. Crooke, S.
Carter and A. Prestayko, eds. Academic Press, N.Y., 271-283, 1980.
The radionuclide used in such studies was 195mPt and the drug was
cisplatin
2. One of the first studies of the pharmacokinetics of 5-Fluorouracil
(using the 18F radiolable) was by Port RE. Strauss LG. Clorius JH:
Positron emission tomography following brief infusion of 5-[18F]
uracil: linear model for the kinetics of 18F radioactivity in tumors.
Onkologie. 12 Suppl 1:51-2, 1989 Aug.
3. A comprehensive publication on noninvasive pharmacokinetics
appeared in 2000, in the March issue of Advanced Drug Delivery
Reviews (volume 41), entitled: Noninvasive Drug Monitoring, and which
included 8 papers discussing both nuclear and NMR (MRI, MRS) methods
--
Professor Walter Wolf, Ph.D. Distinguished Professor of
Pharmaceutical Sciences
Director, Pharmacokinetic Imaging Program
Department of Pharmaceutical Sciences, School of Pharmacy
Chair, Biomedical Imaging Science Initiative
University of Southern California 1985 Zonal Ave., Los Angeles, CA
90089-9121
E-Mail: wwolfw.at.usc.edu
Telephone: 323-442-1405
Fax: 323-442-9804
http://www.usc.edu/research/initiatives/biomedical_imaging/index.html
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)